Administration Subcutaneous injection is the usual path
at least 612 months of intervention, to capture meaningful clinical outcomes rather than short-term surrogate changes), and meaningful primary endpoints (such as improvement in exercise capacity or cardiac function, reduction in hospitalizations or major cardiovascular events, or other hard outcomes like all-cause mortality)
Regulation of FoxO transcription factors by acetylation and protein-protein interactions
*FOR $500M to $600M POTENTIAL SAVINGS OVER 12 MONTHS SOURCE: While we initially estimated about $270M to $390M in client savings, the additional rate improvement we were able to obtain on this strategy suggests that we will save roughly double this amount, $500M to $600M over the 12 months following our change
The timeline depends on dose, tolerance, nutrition, activity, and follow-up consistency